Floatz logo

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID

Acute Coronary Syndrome

SanofiSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Acute Coronary Syndrome cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
Lipitor
Punjab Institute of Cardology
Phase 4BB
Ticagrelor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Phase 4BB
Plavix
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BB
Exenatide
Saint Luke's Health System
Phase 4BB

View all 34 →

Same molecule, other indications

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID is also rated in:

HypercholesterolemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
67 / 100
View asset →
Non Optimal Response to UDCADormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →